network member

North Carolina

About Network Member

Currently Enrolling

HCRN-AML20-472

TAGALONG Trial: Phase II Study of TAGraxofusp and Azacitidine With or Without Venetoclax in Newly Diagnosed Secondary AML after Previous Exposure to HypOmethylatiNG Agents
Cancer areas:Leukemia
AdventHealth Orlando
Rhode Island Hospital
University of North Carolina Lineberger Comprehensive Cancer Center
Currently Enrolling

HCRN-BRE18-360

Phase I/II Study of Stereotactic Radiosurgery With Concurrent Administration of DNA Damage Response (DDR) Inhibitor (OLAparib) Followed by Adjuvant Combination of DuRvalumab (MEDI4736) and Physician’s Choice Systemic Therapy in Subjects With BreAst Cancer Brain Metastases
Cancer areas:Breast
Cleveland Clinic Cancer Center
Duke Cancer Institute
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Memorial Breast Cancer Center at Memorial Regional Hospital
Memorial Sloan Kettering Cancer Center
University of North Carolina Lineberger Comprehensive Cancer Center
Currently Enrolling

HCRN-BRE21-516

BRIDGET: Secondary BRain metastases prevention after Isolated intracranial progression on Trastuzumab/Pertuzumab or T-DM1 in patients with aDvanced human epidermal Growth factor receptor 2+ brEast cancer with the addition of Tucatinib
Cancer areas:Breast
Dana-Farber Cancer Institute
Duke Cancer Institute
MD Anderson Cancer Center
Novant Health Oncology Specialists
Providence Cancer Institute
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine
The Ohio State University
UC San Francisco
University of Michigan Rogel Cancer Center
Currently Enrolling

HCRN-BSK22-562

Observational basket trial to predict response to immune checkpoint inhibitors across solid tumors using a live tumor diagnostic platform (CYBRID-02)
Cancer areas:Basket
AdventHealth Orlando
CARTI
John Theurer Cancer Center at Hackensack Meridian Health
Meritus Center for Clinical Research / John R. Marsh Cancer Center
Salinas Valley Health
University of Louisville / James Graham Brown Cancer Center
University of North Carolina Lineberger Comprehensive Cancer Center
University of Wisconsin Carbone Cancer Center
Currently Enrolling

TBCRC047

Innovative Combination Immunotherapy for Metastatic Triple Negative Breast Cancer (TNBC): A Multicenter, Multi-Arm Translational Breast Cancer Research Consortium Study
Cancer areas:Breast
Dana-Farber Cancer Institute
Duke Cancer Institute
Georgetown Lombardi Comprehensive Cancer Center
Mayo Clinic
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
The University of Chicago Medicine Comprehensive Cancer Center
UC San Francisco
University of Alabama at Birmingham Comprehensive Cancer Center
University of North Carolina Lineberger Comprehensive Cancer Center
Vanderbilt-Ingram Cancer Center
Enrollment Closed

HCRN-BRE18-334

A Phase II circulating tumor DNA enriched, genomically directed post-neoadjuvant trial for patients with residual triple negative breast cancer (PERSEVERE)
Cancer areas:Breast
Advocate Aurora Research Institute (Illinois)
Aurora Health Care
Froedtert & the Medical College of Wisconsin
Georgetown Lombardi Comprehensive Cancer Center
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Miami Cancer Institute at Baptist Health, Inc.
Novant Health Oncology Specialists
The University of Chicago Medicine Comprehensive Cancer Center
University of Alabama at Birmingham Comprehensive Cancer Center
University of Wisconsin Carbone Cancer Center
UT Health San Antonio MD Anderson Cancer Center
Enrollment Closed

HCRN-LUN21-497

A Phase II Study of GT103 in Combination with Pembrolizumab in Refractory, Metastatic Non-Small Cell Lung Cancer
Cancer areas:Lung
Barbara Ann Karmanos Cancer Center
Duke Cancer Institute
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Summit Health Cancer Center
University of Illinois Cancer Center
University of Virginia Cancer Center